Literature DB >> 26277044

Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study.

Carsten Hjorthøj1, Marie Louise Drivsholm Østergaard2, Michael Eriksen Benros2, Nanna Gilliam Toftdahl2, Annette Erlangsen3, Jon Trærup Andersen4, Merete Nordentoft2.   

Abstract

BACKGROUND: People with severe mental illness have both increased mortality and are more likely to have a substance use disorder. We assessed the association between mortality and lifetime substance use disorder in patients with schizophrenia, bipolar disorder, or unipolar depression.
METHODS: In this prospective, register-based cohort study, we obtained data for all people with schizophrenia, bipolar disorder, or unipolar depression born in Denmark in 1955 or later from linked nationwide registers. We obtained information about treatment for substance use disorders (categorised into treatment for alcohol, cannabis, or hard drug misuse), date of death, primary cause of death, and education level. We calculated hazard ratios (HRs) for all-cause mortality and subhazard ratios (SHRs) for cause-specific mortality associated with substance use disorder of alcohol, cannabis, or hard drugs. We calculated standardised mortality ratios (SMRs) to compare the mortality in the study populations to that of the background population.
FINDINGS: Our population included 41 470 people with schizophrenia, 11 739 people with bipolar disorder, and 88 270 people with depression. In schizophrenia, the SMR in those with lifetime substance use disorder was 8·46 (95% CI 8·14-8·79), compared with 3·63 (3·42-3·83) in those without. The respective SMRs in bipolar disorder were 6·47 (5·87-7·06) and 2·93 (2·56-3·29), and in depression were 6·08 (5·82-6·34) and 1·93 (1·82-2·05). In schizophrenia, all substance use disorders were significantly associated with increased risk of all-cause mortality, both individually (alcohol, HR 1·52 [95% CI 1·40-1·65], p<0·0001; cannabis, 1·24 [1·04-1·48], p=0·0174; hard drugs, 1·78 [1·56-2·04], p<0·0001) and when combined. In bipolar disorder or depression, only substance use disorders of alcohol (bipolar disorder, HR 1·52 [95% CI 1·27-1·81], p<0·0001; depression, 2·01 [1·86-2·18], p<0·0001) or hard drugs (bipolar disorder, 1·89 [1·34-2·66], p=0·0003; depression, 2·27 [1·98-2·60], p<0·0001) increased risk of all-cause mortality individually.
INTERPRETATION: Mortality in people with mental illness is far higher in individuals with substance use disorders than in those without, particularly in people who misuse alcohol and hard drugs. Mortality-reducing interventions should focus on patients with a dual diagnosis and seek to prevent or treat substance use disorders. FUNDING: The Lundbeck Foundation.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26277044     DOI: 10.1016/S2215-0366(15)00207-2

Source DB:  PubMed          Journal:  Lancet Psychiatry        ISSN: 2215-0366            Impact factor:   27.083


  34 in total

1.  Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study.

Authors:  Björn Philips; Peter Wennberg; Per Konradsson; Johan Franck
Journal:  Eur Addict Res       Date:  2018-01-19       Impact factor: 3.015

2.  Mortality and Medical Comorbidity in the Severely Mentally Ill.

Authors:  Frank Schneider; Michael Erhart; Walter Hewer; Leonie Ak Loeffler; Frank Jacobi
Journal:  Dtsch Arztebl Int       Date:  2019-06-10       Impact factor: 5.594

3.  Causes and predictors of premature death in first-episode schizophrenia spectrum disorders.

Authors:  Ingrid Melle; Jan Olav Johannesen; Ulrik H Haahr; Wenche Ten Velden Hegelstad; Inge Joa; Johannes Langeveld; Tor K Larsen; Stein Ilner Opjordsmoen; Ping Qin; Jan Ivar Røssberg; Bjørn Rishovd Rund; Erik Simonsen; Per J W Vaglum; Thomas H McGlashan; Svein Friis
Journal:  World Psychiatry       Date:  2017-06       Impact factor: 49.548

4.  Impact of substance use disorder on gray matter volume in schizophrenia.

Authors:  Margaret Quinn; Maureen McHugo; Kristan Armstrong; Neil Woodward; Jennifer Blackford; Stephan Heckers
Journal:  Psychiatry Res Neuroimaging       Date:  2018-08-03       Impact factor: 2.376

5.  How Much Do Mental Health and Substance Use/Addiction Affect Use of General Medical Services? Extent of Use, Reason for Use, and Associated Costs.

Authors:  Kathryn Graham; Joyce Cheng; Sharon Bernards; Samantha Wells; Jürgen Rehm; Paul Kurdyak
Journal:  Can J Psychiatry       Date:  2016-08-20       Impact factor: 4.356

6.  Genetic correlation, pleiotropy, and causal associations between substance use and psychiatric disorder.

Authors:  Seon-Kyeong Jang; Gretchen Saunders; MengZhen Liu; Yu Jiang; Dajiang J Liu; Scott Vrieze
Journal:  Psychol Med       Date:  2020-08-07       Impact factor: 7.723

7.  Patients with stroke and psychiatric comorbidities have lower carotid revascularization rates.

Authors:  Diana M Bongiorno; Gail L Daumit; Rebecca F Gottesman; Roland Faigle
Journal:  Neurology       Date:  2019-05-03       Impact factor: 9.910

8.  Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study.

Authors:  Oleguer Plana-Ripoll; Katherine L Musliner; Søren Dalsgaard; Natalie C Momen; Nanna Weye; Maria K Christensen; Esben Agerbo; Kim Moesgaard Iburg; Thomas Munk Laursen; Preben Bo Mortensen; Carsten Bøcker Pedersen; Liselotte Vogdrup Petersen; Damian F Santomauro; Bjarni J Vilhjálmsson; Harvey A Whiteford; John J McGrath
Journal:  World Psychiatry       Date:  2020-10       Impact factor: 49.548

Review 9.  [Somatic morbidity in the mentally ill].

Authors:  W Hewer; F Schneider
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

10.  Correlates of Physical Activity and Cardiorespiratory Fitness in Racially and Ethnically Diverse People with Serious Mental Illness in Supportive Housing.

Authors:  Leopoldo J Cabassa; Ana Stefancic; Xiaoyan Wang; Shenyang Guo; Nathaniel Young Lu; Christopher Weatherly
Journal:  Community Ment Health J       Date:  2020-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.